Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.

No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One (2013) 0.90

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype. Case Rep Gastroenterol (2015) 0.79

Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response. PLoS One (2014) 0.77

IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol (2013) 0.75

Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol (2015) 0.75

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12

EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology (2010) 4.19

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology (2009) 2.33

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol (1996) 2.24

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology (2009) 2.21

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology (1995) 2.02

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat (2007) 1.89

APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int (2012) 1.79

New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71

Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology (1994) 1.60

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology (2009) 1.34

Immunopathology of hepatitis C. Springer Semin Immunopathol (1997) 1.30

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev (2002) 1.24

Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology (1992) 1.14

Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One (2012) 1.09

Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol (2011) 1.07

Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One (2011) 1.00

Interferon-induced chronic active hepatitis? Gastroenterology (1991) 0.99

Antibody-dependent enhancement of hepatitis C virus infection. J Virol (2007) 0.96

An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen. Autoimmunity (1991) 0.96

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat (2010) 0.96

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat (2010) 0.96

Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin Gastroenterol Hepatol (2004) 0.96

Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol (2007) 0.95

Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res (2011) 0.94

Hepatitis C in patients undergoing liver transplantation. Ann Intern Med (1991) 0.92

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses (2012) 0.89

Acute hepatitis C virus infection, 1986-2001: a rare cause of fulminant hepatitis in Chiba, Japan. Hepatogastroenterology (2004) 0.84

Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother (2003) 0.83

Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatol Int (2012) 0.80

Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. J Viral Hepat (2012) 0.79

Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. J Hepatol (1997) 0.79

Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis (2011) 0.77

Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (2002) 5.71

Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61

A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med (2005) 3.18

Molecular epidemiology of enterovirus 71 infection in the Western Pacific Region. Pediatr Int (2004) 3.06

Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet (2005) 3.01

Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol (2003) 2.90

Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008) 2.74

Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med (2009) 2.73

Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis (2005) 2.55

Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol (2003) 2.51

Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg (2004) 2.47

Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res (2012) 2.45

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology (2003) 2.38

De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol (2013) 2.22

Factors affecting the accuracy of endoscopic transpapillary sampling methods for bile duct cancer. Dig Endosc (2013) 2.09

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology (2003) 2.05

Efficacy of stone density on noncontrast computed tomography in predicting the outcome of extracorporeal shock wave lithotripsy for patients with pancreatic stones. Pancreas (2015) 1.97

Hepatitis C virus genotype 1a growth and induction of autophagy. J Virol (2007) 1.96

Genetic and antigenic diversity among noroviruses. J Gen Virol (2006) 1.91

Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J (2006) 1.89

Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol (2005) 1.86

Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A (2009) 1.82

Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 1.79

Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol (2002) 1.78

Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76

Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol (2003) 1.76

Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. Gastrointest Endosc (2008) 1.74

Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem (2006) 1.71

New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71

Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol (2008) 1.65

Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol (2008) 1.65

Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat Commun (2010) 1.62

Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol (2005) 1.60

Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol (2010) 1.58

Clinical utility of intraductal US to decrease early recurrence rate of common bile duct stones after endoscopic papillotomy. J Gastroenterol Hepatol (2008) 1.56

The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res (2008) 1.56

Callose biosynthesis regulates symplastic trafficking during root development. Dev Cell (2011) 1.55

Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol (2004) 1.55

Diagnostic value of magnetic resonance cholangiopancreatography for clinically suspicious spontaneous passage of bile duct stones. J Gastroenterol Hepatol (2007) 1.49

Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A (2007) 1.45

Heterogeneous staining in the liver parenchyma after the injection of perflubutane microbubble contrast agent. Ultrasound Med Biol (2012) 1.45

Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease. Dig Dis Sci (2013) 1.44

Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol (2005) 1.43

Deficiency in IL-17-committed Vγ4(+) γδ T cells in a spontaneous Sox13-mutant CD45.1(+) congenic mouse substrain provides protection from dermatitis. Nat Immunol (2013) 1.43

Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol (2004) 1.43

Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology (2007) 1.42

Clinicopathological characteristics and prognosis of patients with esophageal carcinoma invading adjacent structures found during esophagectomy. J Surg Oncol (2012) 1.42

Preoperative assessment of longitudinal extension of cholangiocarcinoma with peroral video-cholangioscopy: a prospective study. Dig Endosc (2013) 1.41

Intramembrane proteolysis and endoplasmic reticulum retention of hepatitis C virus core protein. J Virol (2004) 1.40

Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem (2010) 1.40

Old age is associated with increased severity of complications in endoscopic biliary stone removal. Dig Endosc (2014) 1.39

Molecular typing and epidemiology of non-polio enteroviruses isolated from Yunnan Province, the People's Republic of China. J Med Virol (2008) 1.34

A norovirus protease structure provides insights into active and substrate binding site integrity. J Virol (2005) 1.34

Outcomes of simultaneous resection of synchronous esophageal and extraesophageal carcinomas. J Am Coll Surg (2002) 1.31

Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol (2005) 1.31

Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology (2002) 1.30

The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat Immunol (2012) 1.30

Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res (2008) 1.29

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer (2011) 1.27

Nudel binds Cdc42GAP to modulate Cdc42 activity at the leading edge of migrating cells. Dev Cell (2008) 1.26

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat (2014) 1.23

A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol (2005) 1.23

Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology (2007) 1.22

Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol (2005) 1.22

The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol (2009) 1.20

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine (2004) 1.20

E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol (2006) 1.19

Thaxtomin A affects CESA-complex density, expression of cell wall genes, cell wall composition, and causes ectopic lignification in Arabidopsis thaliana seedlings. J Exp Bot (2009) 1.19

Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol (2008) 1.18

Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review. Int J Clin Oncol (2009) 1.16

The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol (2010) 1.16

Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J Virol (2004) 1.16

Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology (2002) 1.16

Gravitropism of Arabidopsis thaliana roots requires the polarization of PIN2 toward the root tip in meristematic cortical cells. Plant Cell (2010) 1.15

Identification of active-site amino acid residues in the Chiba virus 3C-like protease. J Virol (2002) 1.14

Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol (2006) 1.14

Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol (2008) 1.13

Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol (2004) 1.13

Proteolytic processing of sapovirus ORF1 polyprotein. J Virol (2005) 1.13

Heat-shock protein gp96/grp94 is an essential chaperone for the platelet glycoprotein Ib-IX-V complex. Blood (2011) 1.12

Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes. J Virol (2010) 1.11

An essential protein that interacts with endosomes and promotes movement of the SHORT-ROOT transcription factor. Curr Biol (2011) 1.11

Latent infection of a new alphanodavirus in an insect cell line. J Virol (2007) 1.11

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer (2011) 1.11

Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol (2009) 1.11

Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein. J Virol (2006) 1.11

Surveillance for avirulent Newcastle disease viruses in domestic ducks (Anas platyrhynchos and Cairina moschata) at live bird markets in Eastern China and characterization of the viruses isolated. Avian Pathol (2009) 1.11

Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J Hepatol (2008) 1.11

Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol (2007) 1.10

Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol (2002) 1.10

Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription. J Virol (2010) 1.10

Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol (2007) 1.08

Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol (2006) 1.08

Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol (2010) 1.08

Historical, present, and future significance of corticosteroid in the treatment of acute liver failure. Hepatology (2014) 1.08

Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. J Biol Chem (2003) 1.08

Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg (2004) 1.07